-
JNJ-26854165 (Serdemetan) Workflow Guide
2026-09-03
Build more informative p53-pathway experiments with JNJ-26854165 (Serdemetan), an HDM2 antagonist that can separate growth arrest from cell death when paired with time-resolved readouts. This guide covers concentration planning, apoptosis confirmation, radiosensitization workflows, and troubleshooting for reproducible cancer research.
-
Sulfamonomethoxine Workflows for Veterinary Research
2026-09-03
Sulfamonomethoxine (SMM) supports controlled studies of folate-pathway inhibition, veterinary antimicrobial performance, aquaculture exposure, and environmental fate. This practical guide connects reproducible solution preparation and assay design with a pulsed-plasma degradation study, helping researchers distinguish parent-compound removal from residual toxicity.
-
SLC25A1, Senescence, and HNSCC Drug Resistance
2026-09-02
An article in npj Precision Oncology reports that elevated SLC25A1 connects mitochondrial citrate handling with H3K27ac-dependent transcription, cellular senescence, and cisplatin resistance in HNSCC. The study supports SLC25A1 as a candidate biomarker and therapeutic target, while emphasizing that senescence-associated staining should be interpreted alongside orthogonal molecular and functional assays.
-
β-Amanitin: A Mechanistic Guide to RNA Pol II
2026-09-02
β-Amanitin is a precise research tool for dissecting RNA polymerase II activity, mRNA synthesis, and transcriptional control. This guide connects mechanistic cell assays with emerging amatoxin detection while emphasizing assay selection, reproducibility, and safety boundaries.
-
Separating Growth Inhibition from Cancer Cell Killing
2026-09-01
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of an in vitro cancer drug response. This framework helps researchers design time-aware assays and avoid interpreting reduced viability as direct evidence of cytotoxicity.
-
QNZ (EVP4593): A Mechanistic NF-κB Probe
2026-09-01
QNZ (EVP4593) is a nanomolar NF-κB pathway modulator with applications spanning inflammation, Huntington’s disease research, and host–virus biology. This article explains how to use it as a mechanistic perturbation alongside the FLNa–NF-κB findings reported in hepatitis E virus research.
-
Bufalin: Mechanism, TNBC Evidence, and Research Use
2026-08-31
Bufalin is a cardiotonic steroid with documented effects on apoptosis, cell differentiation, and cancer-associated signaling. Current TNBC evidence identifies STK33 binding and degradation as a preclinical mechanism, while product data support controlled research use rather than clinical treatment.
-
Drug Response Metrics in Cancer Research
2026-08-31
Hannah Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different relationships between growth inhibition and cell death. Its central implication is practical: cancer drug studies should define the biological endpoint, track response timing, and avoid interpreting reduced viability as proof of cytotoxicity.
-
Palbociclib Nanocrystals for Local Breast Cancer Therapy
2026-08-30
This study developed palbociclib nanocrystals within a thermoresponsive poloxamer in situ gel to improve local delivery of a poorly soluble CDK4/6 inhibitor. The platform increased dissolution and cellular activity while providing sustained release, offering a formulation strategy for intratumoral breast cancer treatment that still requires in vivo and translational validation.
-
JNJ-26854165: Beyond the Viability Readout
2026-08-29
JNJ-26854165, or Serdemetan, is an HDM2 antagonist whose effects can include growth arrest, apoptosis, and radiosensitization. This article applies a dissertation-derived framework to show how endpoint selection and timing improve interpretation in cancer research.
-
PMSF Workflows for Protease-Safe Protein Extraction
2026-08-28
PMSF provides targeted, irreversible serine protease inhibition for cleaner lysates, stronger Western blot signals, and more reliable protein measurements. This practical guide connects PMSF handling with time-resolved hemocyte, histone-modification, apoptosis, and extracellular-vesicle workflows.
-
Luminescent ATP Cell Viability Assay Kit I
2026-08-28
Learn how Luminescent ATP Cell Viability Assay Kit I, SKU K2041, supports sensitive cell viability measurement, cytotoxicity testing, and metabolism studies. This scenario-driven guide covers assay principles, ferroptosis compatibility, protocol optimization, data interpretation, and practical kit selection.
-
AP20187: Designing Causal Dimerization Assays
2026-08-27
AP20187 is a chemical inducer of dimerization for temporally controlled signaling and conditional gene expression. This guide connects its assay utility with 14-3-3, autophagy, and oncogenic signaling research while defining practical boundaries for interpretation.
-
Self-Amplifying RNA Vaccines for Influenza
2026-08-27
The reference study shows that self-amplifying RNA can overcome important strain-specific immunogenicity limitations of conventional mRNA influenza vaccines, particularly for influenza B. In mouse challenge models, a low-dose trivalent saRNA candidate generated durable antibody responses and complete protection, supporting dose-sparing development while also clarifying the need to separate platform effects from nucleoside chemistry.
-
Cefoperazone: From Mechanism to Translation
2026-08-26
Cefoperazone sodium salt offers translational researchers a useful framework for connecting β-lactamase stability, antibacterial activity against gram-negative bacilli, assay design, and biliary tract infection research. This article interprets historical comparative data alongside practical workflow guidance while distinguishing product characteristics from experimentally validated conclusions.